Rare disease

Anaplastic large cell lymphoma T- and null-cell types

7 clinical trials

Quick filters

Clinical trials for Anaplastic large cell lymphoma T- and null-cell types

7 trials across Europe

See all trials →

Quick filters

7 Clinical trials

Primary mediastinal large B-cell lymphoma+3

Recruiting

Registered drug

Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Placebo
Sponsor:Aalborg University Hospital

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Registered drugNo placebo

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Brigatinib
Sponsor:Princess Maxima Center For Pediatric Oncology

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Registered drugNo placebo

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo

Denmark

Participants:0–17 years · 18–64 years
Substances:Crizotinib
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types

Recruiting

Registered drugNo placebo

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Vinblastine Sulfate
Sponsor:GPOH gGmbH

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types

Not recruiting

Registered drugNo placebo

Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Lorlatinib
Sponsor:Universita Degli Studi Di Milano Bicocca

Contact Research Centre

Anaplastic large cell lymphoma T- and null-cell types

Not recruiting

Registered drugNo placebo

Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma

Registered drugNo placebo

Denmark

Participants:0–17 years · 18–64 years
Substances:Nivolumab
Sponsor:Institut Gustave Roussy

Contact Research Centre

See all trials →

Anaplastic large cell lymphoma T- and null-cell types

Clinical trials for Anaplastic large cell lymphoma T- and null-cell types

Primary mediastinal large B-cell lymphoma+3

Study of dapagliflozin to prevent heart complications during lymphoma treatment in patients receiving first-line therapy

Anaplastic large cell lymphoma T- and null-cell types+1

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Anaplastic large cell lymphoma T- and null-cell types+3

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Anaplastic large cell lymphoma T- and null-cell types

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic large cell lymphoma T- and null-cell types

Study of Lorlatinib for Patients with ALK+ Anaplastic Large Cell Lymphoma After Ineffective ALK Inhibitor Treatment

Anaplastic large cell lymphoma T- and null-cell types

Study of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.